pirfenidone has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Z; Cheng, Z; Hu, G; Jiang, D; Li, Q; Lu, M; Peng, Z; Tao, L; Xiong, X | 1 |
| Brown, L; Dallemagne, C; Endre, Z; Margolin, S; Miric, G; Taylor, SM | 1 |
2 other study(ies) available for pirfenidone and Alloxan Diabetes
| Article | Year |
|---|---|
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship | 2018 |
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Blood Glucose; Body Weight; Calcium Chloride; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drinking; Eating; Fibrosis; Glomerular Filtration Rate; Heart Ventricles; In Vitro Techniques; Kidney; Male; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Norepinephrine; Pyridones; Quinolines; Rats; Rats, Wistar; Spironolactone; Thiadiazines; Vasoconstriction; Vasoconstrictor Agents | 2001 |